Mechanism of action
Amantadine exerts its effects through multiple mechanisms that increase dopaminergic activity in the central nervous system.
Dopaminergic effects: Amantadine enhances dopamine release from presynaptic terminals, inhibits dopamine reuptake, and may stimulate dopamine receptors directly. These actions increase synaptic dopamine availability in the nigrostriatal pathway, alleviating parkinsonian symptoms.
NMDA receptor antagonism: Amantadine is a noncompetitive antagonist at N-methyl-D-aspartate (NMDA) glutamate receptors. Excessive glutamatergic activity is implicated in both parkinsonian symptoms and levodopa-induced dyskinesias. By blocking NMDA receptors, amantadine reduces excitotoxicity and helps restore the balance between dopaminergic and glutamatergic signaling.
Antiviral mechanism: Amantadine blocks the M2 protein ion channel of influenza A virus, preventing viral uncoating and replication within host cells. This mechanism is now largely obsolete due to widespread viral resistance.
Anticholinergic activity: Amantadine possesses mild anticholinergic properties that may contribute to its antiparkinsonian effects by reducing the relative cholinergic excess seen in Parkinson disease.
- Amantadine increases dopamine release and blocks NMDA receptors, used for Parkinson disease and levodopa-induced dyskinesias.
- Livedo reticularis (mottled purplish skin discoloration on legs) is a characteristic and testable adverse effect.
- Renally excreted unchanged; dose adjustment mandatory in renal impairment to avoid toxicity.
- Abrupt withdrawal can precipitate neuroleptic malignant syndrome-like reaction with fever, rigidity, and altered consciousness.
- Only medication proven effective for reducing levodopa-induced dyskinesias in Parkinson disease.
- Neuropsychiatric effects (confusion, hallucinations, insomnia) are common, especially in elderly patients.
- No longer recommended for influenza A due to widespread viral resistance; neuraminidase inhibitors preferred.
- Peripheral edema and orthostatic hypotension are common cardiovascular adverse effects.
Indications
Amantadine has several neurological and antiviral indications, though its use has shifted over time.
Parkinson disease: Used as monotherapy in early disease or as adjunctive therapy with levodopa. Amantadine provides modest symptomatic benefit for tremor, rigidity, and bradykinesia. It is particularly useful when patients experience motor fluctuations.
Levodopa-induced dyskinesias: Amantadine is the only agent with evidence for reducing troublesome dyskinesias in patients on chronic levodopa therapy. It allows continued levodopa use while improving quality of life.
Drug-induced extrapyramidal symptoms: Effective for managing extrapyramidal side effects caused by antipsychotic medications, including acute dystonia, akathisia, and parkinsonism.
Influenza A prophylaxis and treatment: Previously used for influenza A prevention and early treatment, but high rates of resistance among circulating strains have made this indication obsolete. Current guidelines do not recommend amantadine for influenza.
Off-label uses: Traumatic brain injury, multiple sclerosis-related fatigue, and certain movement disorders have been explored, though evidence is limited.
Pharmacokinetics
Absorption: Amantadine is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring 2 to 4 hours after oral administration. Bioavailability approaches 90 percent.
Distribution: The drug distributes widely throughout the body, including penetration into the central nervous system. It crosses the blood-brain barrier and achieves therapeutic CNS concentrations. Volume of distribution is large, reflecting extensive tissue distribution.
Metabolism: Amantadine undergoes minimal hepatic metabolism. The majority of the drug is excreted unchanged, making it less susceptible to drug interactions involving hepatic enzymes.
Elimination: Renal excretion is the primary route of elimination. Amantadine is excreted unchanged in the urine via glomerular filtration and tubular secretion. The elimination half-life is approximately 15 to 17 hours in healthy adults but is significantly prolonged in renal impairment. Dose adjustment is essential in patients with reduced creatinine clearance to avoid toxic accumulation.
Special populations: Elderly patients often have reduced renal function and are at higher risk for adverse effects. Dosing should be conservative and adjusted based on renal function.
Adverse effects
Amantadine has a distinct adverse effect profile that reflects its multiple mechanisms of action.
Neuropsychiatric effects: Common and dose-related. Patients may experience:
- Insomnia, vivid dreams, nightmares
- Anxiety, nervousness, irritability
- Confusion, hallucinations, delirium (especially in elderly)
- Difficulty concentrating
Livedo reticularis: A characteristic mottled, purplish discoloration of the skin, particularly on the lower extremities. This is a benign but cosmetic concern that usually resolves after discontinuation.
Peripheral edema: Ankle swelling occurs in a significant proportion of patients and may require diuretic therapy or dose reduction.
Cardiovascular: Orthostatic hypotension is common. Rare cases of cardiac arrhythmias and heart failure exacerbation have been reported.
Anticholinergic effects: Dry mouth, urinary retention, constipation, and blurred vision may occur due to mild anticholinergic activity.
Gastrointestinal: Nausea, anorexia, and constipation are reported.
Neuroleptic malignant syndrome-like reaction: Abrupt withdrawal of amantadine in Parkinson patients can precipitate a syndrome resembling neuroleptic malignant syndrome, with fever, rigidity, altered consciousness, and elevated creatine kinase. The drug should be tapered gradually.
Impulse control disorders: Like other dopaminergic agents, amantadine has been associated with pathological gambling, hypersexuality, and compulsive behaviors, though less commonly than dopamine agonists.
Contraindications and warnings
Contraindications:
- Hypersensitivity to amantadine or any component of the formulation
- End-stage renal disease without dialysis access
Warnings and precautions:
Renal impairment: Dose adjustment is mandatory. Accumulation leads to toxicity, particularly CNS effects. Creatinine clearance should be assessed before initiating therapy and monitored periodically.
Psychiatric disorders: Use with caution in patients with a history of psychosis, severe psychoneurosis, or seizure disorders. Amantadine can precipitate or worsen hallucinations, confusion, and agitation.
Cardiovascular disease: Monitor for orthostatic hypotension, peripheral edema, and heart failure exacerbation. Caution is advised in patients with congestive heart failure or peripheral edema.
Abrupt discontinuation: Tapering is essential to avoid acute worsening of parkinsonian symptoms or a neuroleptic malignant syndrome-like picture.
Pregnancy and lactation: Pregnancy category C. Amantadine is teratogenic in animal studies. Use only if potential benefit justifies fetal risk. The drug is excreted in breast milk; breastfeeding is not recommended.
Elderly patients: Increased sensitivity to CNS and anticholinergic effects. Start at low doses and titrate cautiously.
Impulse control: Counsel patients and caregivers about the risk of pathological gambling and other compulsive behaviors.
Drug interactions
Amantadine has relatively few major drug interactions due to minimal hepatic metabolism, but clinically significant interactions can occur.
Anticholinergic agents: Concurrent use with anticholinergics (e.g., benztropine, trihexyphenidyl, antihistamines, tricyclic antidepressants) can potentiate anticholinergic side effects including dry mouth, urinary retention, constipation, confusion, and hallucinations. This combination is particularly risky in the elderly.
CNS stimulants: Additive CNS stimulation with agents like amphetamines or methylphenidate may increase the risk of insomnia, nervousness, tremor, and seizures.
Alcohol: CNS effects of alcohol may be potentiated. Increased risk of dizziness, confusion, and orthostatic hypotension.
Diuretics: Thiazide diuretics and triamterene can reduce renal clearance of amantadine, leading to increased plasma levels and toxicity. Monitor closely and consider dose reduction.
Dopaminergic agents: Additive dopaminergic effects with levodopa or dopamine agonists may worsen dyskinesias or psychiatric symptoms. Dosing adjustments may be necessary.
Bupropion and memantine: Both are also NMDA antagonists. Theoretical risk of additive effects, though clinical significance is unclear.
Live attenuated influenza vaccine: Amantadine may inhibit the replication of live vaccine virus. Avoid concurrent use or separate administration by at least 48 hours (though this is now largely theoretical given amantadine's discontinued antiviral use).
Clinical pearls
Dual mechanism utility: Amantadine's combination of dopaminergic and NMDA antagonist activity makes it unique among antiparkinsonian drugs. It is the only medication with proven efficacy for levodopa-induced dyskinesias.
Livedo reticularis as a clue: The appearance of mottled, lacy, purplish skin discoloration on the legs is pathognomonic for amantadine use and should prompt recognition on clinical exams.
Tolerance development: Some patients experience a wearing-off effect after several months of use, requiring dose adjustment or drug holidays. This is particularly true for the antiparkinsonian effects.
Renal dosing is critical: Because amantadine is renally cleared, failure to adjust the dose in renal impairment leads to toxicity. Always calculate creatinine clearance before prescribing.
Withdrawal syndrome: Abrupt discontinuation can cause a parkinsonian crisis or neuroleptic malignant syndrome-like reaction. Taper over at least one week.
Antiviral use is obsolete: Due to widespread resistance, amantadine is no longer recommended for influenza prophylaxis or treatment. Neuraminidase inhibitors like oseltamivir are preferred.
First-line for dyskinesias: When patients on chronic levodopa develop troublesome dyskinesias, amantadine should be considered before reducing levodopa dose, as it allows maintenance of motor benefit.
Monitor mental status in elderly: Confusion and hallucinations are more common in older adults. Start low, go slow, and maintain a high index of suspicion for cognitive changes.
Impulse control screening: Regularly screen patients for new gambling urges, hypersexuality, compulsive shopping, or binge eating, especially during dose escalation.
AMANTADINE: A MANic drug That Alters Dopamine In Neurons (highlights dopamine mechanism and neuropsychiatric side effects including mania/agitation)
Practice questions
1. A 68-year-old man with Parkinson disease has been on carbidopa-levodopa for 5 years with good motor control. Over the past 6 months, he has developed involuntary, choreiform movements of his limbs and trunk that occur during peak levodopa effect. The movements are distressing and interfere with daily activities. His neurologist wants to add a medication to reduce these dyskinesias without discontinuing levodopa. Which of the following is the most appropriate addition to his regimen?
2. A 72-year-old woman with Parkinson disease started on amantadine 3 weeks ago. She returns to clinic reporting improved tremor but now complains of a purple, lacy discoloration on both lower legs that appeared over the past week. The discoloration is non-tender and blanches with pressure. Her vital signs are normal, and lower extremity pulses are intact. Which of the following is the most likely diagnosis?
3. A 45-year-old man with schizophrenia treated with haloperidol develops acute-onset torticollis and difficulty swallowing. He is started on amantadine for drug-induced dystonia with good response. Three months later, his psychiatrist abruptly discontinues amantadine without tapering. Two days later, the patient presents to the emergency department with fever to 39.5°C, severe muscle rigidity, altered mental status, and elevated creatine kinase. Which of the following best explains this presentation?
Frequently asked questions
How does amantadine work?
Amantadine works through two main mechanisms: it increases dopamine release and inhibits dopamine reuptake in the brain, and it blocks NMDA glutamate receptors. These actions help restore the balance between dopamine and glutamate in Parkinson disease, improving motor symptoms like tremor and rigidity. The NMDA antagonism is particularly important for reducing levodopa-induced dyskinesias.
What are the side effects of amantadine?
Common side effects include livedo reticularis (mottled purple skin discoloration, especially on the legs), peripheral edema (ankle swelling), and neuropsychiatric effects such as insomnia, vivid dreams, confusion, and hallucinations. Orthostatic hypotension, dry mouth, and nausea can also occur. Elderly patients are at higher risk for confusion and delirium. Abrupt discontinuation can cause a dangerous withdrawal syndrome resembling neuroleptic malignant syndrome.
Is amantadine still used for the flu?
No, amantadine is no longer recommended for influenza treatment or prevention. Widespread resistance among circulating influenza A strains has made it ineffective. Current guidelines recommend neuraminidase inhibitors like oseltamivir (Tamiflu) or zanamivir for influenza instead. Amantadine is now used primarily for Parkinson disease and drug-induced movement disorders.
What is amantadine used for in Parkinson disease?
Amantadine is used in Parkinson disease for two main purposes: as monotherapy or adjunct therapy for motor symptoms (tremor, rigidity, bradykinesia) in early or advanced disease, and specifically to reduce levodopa-induced dyskinesias in patients on chronic levodopa therapy. It is the only medication proven effective for dyskinesias, allowing patients to continue levodopa while improving involuntary movements.
Amantadine vs levodopa — what is the difference?
Levodopa is a dopamine precursor that directly replenishes dopamine in the brain and is the most effective treatment for Parkinson motor symptoms, while amantadine indirectly increases dopamine through enhanced release and reuptake inhibition plus NMDA receptor blockade. Levodopa provides stronger symptom control but commonly causes dyskinesias with long-term use. Amantadine has modest motor benefit but uniquely treats levodopa-induced dyskinesias, making it complementary rather than a replacement for levodopa.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N04BB01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.